Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luminate Study: TACE + SBRT + PD-1/L1 Inhibitor + Donafenib in Unresectable HCC
NCT07230314Phase 2Not yet recruiting
- Sponsor
- Jinling Hospital
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Jinling Hospital. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07230314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230314.